Logo
Kairax™ Sub Q (1x1ml)

Kairax™ Sub Q (1x1ml)

Kairax

Dermal filler
  • CE Certified hyaluronic acid dermal filler (Class III medical device) for professional use.
  • Uses HA, BDDE and lidocaine raw materials approved by EDQM (as described in manufacturer/exporter technical listings).
  • Part of the Kairax filler system (Fine, Deep, Sub Q), all promoted as fully CE approved and containing lidocaine for enhanced comfort.
  • Manufactured in South Korea under medical device quality systems and exported globally via LINKUS GLOBAL Co., Ltd. and other authorised partners.
High-viscosity hyaluronic acid dermal filler for deep volumising and contouring

Description

Kairax™ Sub Q (1x1ml) is a CE-certified, high-density hyaluronic acid dermal filler with lidocaine, designed for deep-layer volumising, lifting and structural restoration. As the highest-viscoelasticity product in the Kairax range (Fine, Deep, Sub Q), it is formulated with 24 mg/ml cross-linked HA and 0.3% lidocaine to provide powerful lifting capacity, strong structural support and enhanced patient comfort. Engineered for injection into the deep dermis or subcutaneous tissue, Kairax Sub Q is ideal for contouring and augmenting cheeks, jawline, chin, nasolabial folds, midface and selected body contouring indications. The cohesive, mouldable gel integrates smoothly with surrounding tissues, delivering dramatic yet natural-looking enhancement, improved symmetry and long-lasting definition, with minimal swelling and bruising.

Bnefits

  • High-viscosity, high-viscoelasticity HA gel optimised for deep volumising and contouring.
  • Formulated with 24 mg/ml cross-linked hyaluronic acid for strong lifting capacity and structural support.
  • Contains 0.3% lidocaine for improved patient comfort during injection.
  • Designed for volumising and sculpting cheeks, chin, jawline, nasolabial folds and for selected body contouring areas.
  • Cohesive, mouldable gel allows precise shaping and contour refinement with stable, predictable results.
  • Advanced cross-linking and purified HA provide long-lasting results, typically over 12 months.
  • Biocompatible, non-animal derived HA with excellent water-retention capacity, supporting hydration and durability.
  • High viscoelasticity and plastic consistency help maintain volume and projection while minimising migration.
  • Clinically oriented design aimed at minimal swelling, less bruising and natural, balanced facial enhancements.
  • Supplied in a sterile, ready-to-use 1 ml syringe for controlled, smooth extrusion and convenient professional use.

Indications

  • Deep-layer volumising and lifting of facial structures.
  • Contour and volume enhancement of cheeks and midface.
  • Jawline contouring and definition.
  • Chin augmentation and projection.
  • Correction of deep nasolabial folds and other deep facial folds.
  • Restoration of significant facial volume loss and hollows (e.g. midface, lateral face).
  • Selected non-surgical body contouring indications (e.g. small-volume contouring areas) when permitted by local regulations and clinical protocols.
  • Advanced facial sculpting for patients seeking pronounced yet natural-looking structural enhancement.

Composition

  • Cross-linked hyaluronic acid (HA) 24 mg/ml.
  • Lidocaine hydrochloride 0.3% (local anaesthetic).
  • BDDE (1,4-butanediol diglycidyl ether) as cross-linking agent, with residual BDDE reported as not detected in distributor specifications.
  • Physiological buffer solution and excipients appropriate for sterile, injectable HA fillers.

Formulation

  • Monophasic, highly cross-linked hyaluronic acid gel with high viscoelasticity for deep structural support.
  • HA concentration 24 mg/ml with 0.3% lidocaine for analgesia.
  • High-density, cohesive gel designed for injection into deep dermis or subcutaneous tissue.
  • Non-animal derived, biocompatible and biodegradable HA with strong water-binding capacity (up to 1000 times its own weight as described in Kairax technical literature).
  • Sterile, pyrogen-free, isotonic formulation manufactured under pharmaceutical-grade medical device standards.

Packaging

  • Box containing 1 x 1 ml prefilled glass syringe of Kairax™ Sub Q with lidocaine.
  • Typically supplied with 2 x 25G needles for deep dermal/subcutaneous injection.
  • Outer carton labelled with product name, HA concentration (24 mg/ml), lidocaine content (0.3%), batch/lot number, expiry date and CE mark.
  • Includes instructions for use (IFU) covering indications, contraindications, injection depths, precautions and storage guidelines.
  • Traceability labels supplied for inclusion in patient records and clinic documentation.

Usage

  • For use exclusively by appropriately trained and qualified healthcare professionals experienced in dermal filler injections and advanced facial anatomy.
  • Inspect the blister, syringe and needles prior to use; do not use if packaging is damaged, compromised or beyond the expiry date.
  • Prepare the treatment area with thorough cleansing and disinfection, and maintain strict aseptic technique throughout the procedure.
  • Attach the supplied 25G needle(s) using the Luer-lock connection and prime the syringe by expelling a small amount of gel to remove air.
  • Recommended injection depth for Kairax Sub Q is deep dermis or subcutaneous tissue, depending on the anatomical area and desired volumising effect.
  • Use appropriate injection techniques such as linear threading, fanning, depot/bolus injections or cannula methods for structural support (e.g. along the jawline, in the chin, over the zygomatic arch).
  • Inject slowly with low, controlled pressure and consider aspiration where appropriate to reduce the risk of intravascular injection.
  • Use conservative volumes and build up gradually to avoid overcorrection, especially in new patients or in high-visibility areas.
  • After injection, gently mould and contour the product as needed to achieve smooth, symmetrical and natural-looking results, avoiding excessive pressure or manipulation.
  • Advise patients to avoid touching or massaging the treated area, strenuous exercise, alcohol and exposure to extreme heat or cold for at least 24 hours post-treatment, and to follow clinic-specific aftercare instructions.
  • Always refer to the official Kairax brochure/IFU and comply with local clinical guidelines, insurer requirements and regulatory standards.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics or any component of the product.
  • History of severe allergic reactions or anaphylaxis unless thoroughly assessed and managed with appropriate precautions.
  • Active infection, inflammation or skin disease at or near the intended injection site (e.g. herpes simplex, acne, dermatitis, cellulitis).
  • Autoimmune disease, immunosuppression or uncontrolled systemic illness without specialist evaluation and explicit approval.
  • Bleeding disorders or concurrent use of anticoagulant/antiplatelet therapy that significantly increases bleeding risk, unless appropriately managed.
  • Pregnancy or breastfeeding, as safety has not been established in these populations.
  • Patients under 18 years of age.
  • Injection into blood vessels, intramuscularly, or into areas with permanent fillers or foreign bodies without careful assessment of risk.
  • Known porphyria, significant cardiac conduction abnormalities or other conditions in which lidocaine is contraindicated.
  • Any additional contraindications or warnings detailed in the official Kairax Sub Q instructions for use.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness, swelling, pain, tenderness, itching, bruising or small haematoma, typically resolving within a few days to a week.
  • Temporary lumps, nodules, induration or firmness at or near the injection site, generally improving over time and with gentle massage if advised.
  • Asymmetry, overcorrection or undercorrection that may require adjustment or follow-up treatment.
  • Rare delayed inflammatory or granulomatous reactions, as may occur with other HA fillers, potentially requiring medical management.
  • Infection at the injection site if aseptic technique is not correctly followed.
  • Very rare but serious complications from inadvertent intravascular injection, including vascular occlusion, tissue ischaemia and necrosis, and in high-risk areas potential visual disturbance or blindness.
  • Systemic lidocaine-related effects (e.g. CNS or cardiovascular symptoms) are possible if maximum safe doses are exceeded or if significant intravascular injection occurs, though such events are uncommon at standard aesthetic doses.

Storage Conditions

  • Store at 2–25°C in a clean, dry environment.
  • Do not freeze.
  • Keep the syringe in its original blister and outer carton to protect from light and physical damage until use.
  • Do not use after the expiry date printed on the packaging.
  • Single-use, sterile medical device: do not resterilise and do not reuse any remaining product, syringe or needles.
  • Dispose of used needles and syringes in approved sharps containers and in accordance with local clinical waste regulations.

Duration

Distributor and clinical information for Kairax Sub Q consistently report long-lasting results, typically over 12 months, with many patients maintaining significant volume and contour for 12\u201318 months depending on area treated, injection technique, volume used and individual metabolic factors.

Onset

Provides immediate visible volumising and contour enhancement upon injection, with final appearance refined over several days as transient swelling or redness resolves and the gel integrates with surrounding tissues.

Browse more Dermal filler

Top Treatments

Top Cities in the UK